Skip to main content

GSK slashes workforce

In another move to encourage innovation while trimming its research and development budget, pharmaceutical company GlaxoSmithKline has announced that it will cut two percent, or 350 jobs, from its global R&D staff, according to linkurl:__The Wall Street Journal__.;https://online.wsj.com/article/SB121318410957563897.html?mod=hps_us_at_glance_health "These changes are part of GSK's longer-term strategy to ensure that we invest in key areas of future growth and evolve our business to compete effect

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
In another move to encourage innovation while trimming its research and development budget, pharmaceutical company GlaxoSmithKline has announced that it will cut two percent, or 350 jobs, from its global R&D staff, according to linkurl:__The Wall Street Journal__.;https://online.wsj.com/article/SB121318410957563897.html?mod=hps_us_at_glance_health "These changes are part of GSK's longer-term strategy to ensure that we invest in key areas of future growth and evolve our business to compete effectively in what is a rapidly changing and challenging environment for pharmaceutical companies," a GSK spokesman told __The Wall Street Journal__. This news comes on the heels of an linkurl:announcement;https://www.the-scientist.com/blog/display/54738/ from GSK that it will be "more biotech-like," providing incentives and disincentives to researchers searching for marketable drug discoveries. Three GSK research labs, in the U.S., Britain and Italy, will be affected by the cuts, which are part of a GSK plan to save 1.37 billion a year by 2010.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
November digest cover
November 2026

Chemistry Meets Arcade Combat in “Reaction Rumble” Game

Choose your fighter! Enter the arena as chemical elements and dole out moves inspired by real-world reactions in this educational browser-based game.

View this Issue
From Pilot to Practice: Advancing Regulatory Reliance

From Pilot to Precedent: A Year of Regulatory Innovation through PRISM and What it Means for Cloud Adoption in Regulatory Submissions

DNAnexus
Thumbnail

Make It Local, Make It Last: The Evolution of mRNA Protein Replacement Therapy

Improving Western Blot Analysis of Biofluid Samples

Improving Western Blot Analysis of Biofluid Samples

Bio-Rad
Reducing AAV Sample Consumption With Multiwavelength SV-AUC

Reducing AAV Sample Consumption With Multiwavelength SV-AUC

​Beckman Coulter

Products

Sino Biological Logo

Sino Biological Advances AI-Designed Molecule Validation with 4RISE™

Abstract image of circles and concentric lines on a blue and pink background.

MX Analytical and Precision Balances: Effortless Weighing and Secure Data Handling

Mettler
3D multicolored conceptual image of antibody molecules

Premium BsAb: LC-MS-Assisted Bispecific Antibody Production with >98% Heterodimer Purity

WuXi Biologics
Abstract conceptual image of AI technology for medical science research.

Exploring a New Era of Pharmaceutical Innovation